- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Aliquots are pre-aliquoted, commercially available drugs from the EU. Our aliquots thus contain therapeutic molecules manufactured by the original drug license holder and repackaged by Evidentic.
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
12/2019 |
126,90 € |
||
CD20 |
Monoclonal Antibody |
MabThera® |
10 mg/mL |
– |
2 mg |
-80°C |
07/2021 |
126,90 € |
||
CD20 |
Biosimilar , Monoclonal Antibody |
Rixathon® |
10 mg/mL |
– |
2 mg |
-80 °C |
03/2026 |
311,00 € |
||
TPO receptor (cMpl) |
Peptibody , Therapeutic peptides |
Nplate® |
0,5 mg/mL |
– |
0,02 mg |
-80°C |
05/2025 |
613,00 € |
||
Trop-2-directed ADC |
Antibody-drug conjugate (ADC) |
Trodelvy® |
10 mg/mL |
– |
4 mg |
-80°C |
08/2025 |
299,00 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
yes |
6 mg |
-80°C |
11/2022 |
324,90 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
12/2017 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
02/2019 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6mg |
-80°C |
12/2022 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
03/2018 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
09/2019 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
06/2018 |
301,50 € |
||
IL-17A |
Monoclonal Antibody |
Cosentyx® |
150 mg/mL |
– |
6 mg |
-80°C |
12/2018 |
301,50 € |
||
IL-6 |
Monoclonal Antibody |
Sylvant® |
20 mg/mL |
– |
2 mg |
-80°C |
02/2023 |
199,80 € |
||
CD3 , TCR targeting domain |
Bispecific fusion protein |
Kimmtrak® |
0,2 mg/mL |
– |
0.01 mg |
tba |
tba |
4.602,00 € |
||
B cell maturation antigen , CD3 |
Bispecific Antibody |
Tecvayli® |
10 mg/mL |
– |
0,5 mg |
tba |
tba |
303,00 € |
||
Tissue factor (TF) |
Antibody-drug conjugate (ADC) |
Tivdak® |
10 mg/mL |
– |
1 mg |
tba |
tba |
1.665,00 € |
||
SARS-CoV-2 Spike |
Monoclonal Antibody |
Evusheld® |
100 mg/mL |
– |
4 mg |
tba |
tba |
515,00 € |
||
IL-6 receptor |
Monoclonal Antibody |
RoActemra® |
20 mg/mL |
– |
2 mg |
-80°C |
10/2021 |
115,20 € |
||
IL-6 receptor |
Monoclonal Antibody |
RoActemra® |
20 mg/mL |
– |
2 mg |
-80°C |
05/2018 |
115,20 € |
||
IL-6 receptor |
Monoclonal Antibody |
RoActemra® |
20 mg/mL |
– |
2 mg |
-80°C |
03/2019 |
115,20 € |
||
IL-6 receptor |
Monoclonal Antibody |
RoActemra® |
20 mg/mL |
– |
2 mg |
-80°C |
05/2019 |
115,20 € |
||
IL-6 receptor |
Monoclonal Antibody |
RoActemra® |
20 mg/mL |
– |
2 mg |
-80°C |
03/2020 |
115,20 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Herzuma® |
21 mg/mL |
– |
6 mg |
tba |
tba |
356,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ontruzant® |
21 mg/mL |
– |
2 mg |
tba |
tba |
159,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Kanjinti® |
21 mg/mL |
– |
6 mg |
-80°C |
01/2025 |
356,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Zercepac® |
21 mg/mL |
– |
6 mg |
-80°C |
08/2026 |
356,00 € |
||
HER2 |
Biosimilar , Monoclonal Antibody |
Ogivri® |
21 mg/mL |
– |
6 mg |
-80°C |
10/2025 |
356,00 € |
||
HER2 |
Antibody-drug conjugate (ADC) |
Enhertu® |
20 mg/mL |
– |
2 mg |
tba |
tba |
528,00 € |
||
HER2 |
Antibody-drug conjugate (ADC) |
Kadcyla® |
20 mg/mL |
– |
2 mg |
-80°C |
07/2023 |
348,30 € |
Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin